explore -WSS

explore

author：Wikipedia 2025-10-01 18:24:33 - browse：6

Without question, the new federal law banning surprise billing is achieving its goal of protecting patients from enormous medical bills. But in doing so, the measure, which was initially projected to lower federal spending, appears to be raising costs elsewhere.

The Biden administration’s new progress report on the process for arbitrating disagreements between insurance companies and providers, which covers the first six months of 2023, shows that in over 80% of payment disputes, the arbiter settled on an amount that was more than the median in-network rate for that service. In other words, insurers were ordered to pay more to an out-of-network provider than they’d pay to a contracted one. Not only that, the sheer volume of disputes means the three federal agencies that run the program are devoting much more time to it than expected.

“It raises concerns for folks that envisioned the arbitration process as helping to moderate costs rather than be a tool these companies can leverage to obtain even higher payments,” said Zachary Baron, the director of Georgetown University’s Health Policy and Law Initiative.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Cytokinetics CEO stresses company can launch heart drug on its own

WSS

Helping hospitals and community health centers plan for resilience

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Adam's Take: Intra

Testing GLP

With measles on the rise, a personal story of a devastating disease

hotspot

explore

hotspot

Drug repurposing or repositioning? The language matters

With Wegovy coverage, Medicare patients may face high costs

Hepatitis C has a cure — but many Americans still lack access to it

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Drug repurposing or repositioning? The language matters

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Drug repurposing or repositioning? The language matters

CRISPR technology availability, affordability needs to be expanded

Medical records are filled with copy

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Wikipedia

Wearables generate powerful data but its not useful to doctors, yet

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

It's time to retire 'poor historian' from clinicians' vocabularies

Testing GLP

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Biotech investment managers search for lucrative opportunities

Wikipedia

explore

hotspot

knowledge